[go: up one dir, main page]

WO2015073709A3 - Détection du risque de maladie cardiovasculaire athéroscléreuse et du risque d'insuffisance cardiaque - Google Patents

Détection du risque de maladie cardiovasculaire athéroscléreuse et du risque d'insuffisance cardiaque Download PDF

Info

Publication number
WO2015073709A3
WO2015073709A3 PCT/US2014/065524 US2014065524W WO2015073709A3 WO 2015073709 A3 WO2015073709 A3 WO 2015073709A3 US 2014065524 W US2014065524 W US 2014065524W WO 2015073709 A3 WO2015073709 A3 WO 2015073709A3
Authority
WO
WIPO (PCT)
Prior art keywords
cardiovascular disease
detection
atherosclerotic cardiovascular
disease risk
ascvd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/065524
Other languages
English (en)
Other versions
WO2015073709A2 (fr
Inventor
Daniel Levy
Ralph B. D'AGOSTINO
Jennifer E. HO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston University
US Department of Health and Human Services
Original Assignee
Boston University
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston University, US Department of Health and Human Services filed Critical Boston University
Publication of WO2015073709A2 publication Critical patent/WO2015073709A2/fr
Publication of WO2015073709A3 publication Critical patent/WO2015073709A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne des méthodes permettant de déterminer la probabilité qu'un sujet développe une maladie cardiovasculaire athéroscléreuse (ASCVD) ou une insuffisance cardiaque (HF). L'invention concerne également des méthodes permettant de déterminer si un agent pharmaceutique est efficace pour le traitement ou la prévention de l'ASCVD ou de l'HF.
PCT/US2014/065524 2013-11-14 2014-11-13 Détection du risque de maladie cardiovasculaire athéroscléreuse et du risque d'insuffisance cardiaque Ceased WO2015073709A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361904410P 2013-11-14 2013-11-14
US61/904,410 2013-11-14

Publications (2)

Publication Number Publication Date
WO2015073709A2 WO2015073709A2 (fr) 2015-05-21
WO2015073709A3 true WO2015073709A3 (fr) 2015-08-27

Family

ID=52144850

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/065524 Ceased WO2015073709A2 (fr) 2013-11-14 2014-11-13 Détection du risque de maladie cardiovasculaire athéroscléreuse et du risque d'insuffisance cardiaque

Country Status (1)

Country Link
WO (1) WO2015073709A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11143659B2 (en) 2015-01-27 2021-10-12 Arterez, Inc. Biomarkers of vascular disease
WO2022046873A1 (fr) 2020-08-25 2022-03-03 Regeneron Pharmaceuticals, Inc. Traitement du sepsis au moyen de modulateurs de pcsk9 et de ldlr
CN112194724B (zh) * 2020-10-19 2022-01-14 福州迈新生物技术开发有限公司 抗mpo蛋白单克隆抗体、细胞系及其制备方法和应用
EP4356142A4 (fr) * 2021-06-16 2025-07-23 Endothelium Scanning Nanotechnology Ltd Biomarqueurs et combinaisons de médicaments pour la prédiction de l'insuffisance cardiaque

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232385A1 (en) * 2002-06-17 2003-12-18 Breit Samuel N. Methods of diagnoisis, prognosis and treatment of cardiovascular disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985001051A1 (fr) 1983-09-02 1985-03-14 Molecular Biosystems, Inc. Systeme de support polymere d'oligonucleotides
GB8810400D0 (en) 1988-05-03 1988-06-08 Southern E Analysing polynucleotide sequences
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5219727A (en) 1989-08-21 1993-06-15 Hoffmann-Laroche Inc. Quantitation of nucleic acids using the polymerase chain reaction
US5554501A (en) 1992-10-29 1996-09-10 Beckman Instruments, Inc. Biopolymer synthesis using surface activated biaxially oriented polypropylene
DK0700521T3 (da) 1993-05-28 2003-09-29 Baylor College Medicine Fremgangsmåde og massespektrometer til desorption og ionisering af analysander
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
DE69503126T2 (de) 1994-05-05 1998-11-12 Beckman Instruments Inc Repetitive oligonukleotide matrix
US5716784A (en) 1996-02-05 1998-02-10 The Perkin-Elmer Corporation Fluorescence detection assay for homogeneous PCR hybridization systems
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
US5985567A (en) 1997-08-15 1999-11-16 Beckman Coulter, Inc. Hybridization detection by pretreating bound single-stranded probes
US6013789A (en) 1998-02-20 2000-01-11 Beckman Coulter, Inc. Covalent attachment of biomolecules to derivatized polypropylene supports
CA2368247A1 (fr) 1999-04-27 2000-11-09 Ciphergen Biosystems, Inc. Sondes pour spectrometre d'ions en phase gazeuse

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232385A1 (en) * 2002-06-17 2003-12-18 Breit Samuel N. Methods of diagnoisis, prognosis and treatment of cardiovascular disease

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
G. A. BONATERRA ET AL: "Growth Differentiation Factor-15 Deficiency Inhibits Atherosclerosis Progression by Regulating Interleukin-6-Dependent Inflammatory Response to Vascular Injury", JOURNAL OF THE AMERICAN HEART ASSOCIATION, vol. 1, no. 6, 13 December 2012 (2012-12-13), pages e002550 - e002550, XP055167960, DOI: 10.1161/JAHA.112.002550 *
KAI M. EGGERS: "Relations of growth-differentiation factor-15 to biomarkers reflecting vascular pathologies in a population-based sample of elderly subjects, Scandinavian Journal of Clinical & Laboratory Investigation, Informa Healthcare", 1 February 2012 (2012-02-01), XP055168093, Retrieved from the Internet <URL:http://informahealthcare.com/doi/abs/10.3109/00365513.2011.626072> [retrieved on 20150206] *
KATHLEEN M. EYSTER ET AL: "Gene expression signatures differ with extent of atherosclerosis in monkey iliac artery", MENOPAUSE, vol. 18, no. 10, 1 October 2011 (2011-10-01), pages 1087 - 1095, XP055167966, ISSN: 1072-3714, DOI: 10.1097/gme.0b013e3182163fea *
LEVY DANIEL ET AL: "Protein Biomarkers of New-Onset Atherosclerotic Cardiovascular Disease", CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 128, no. 22, suppl, 18 November 2013 (2013-11-18), pages 15535, XP009182154, ISSN: 0009-7322 *
V. XANTHAKIS ET AL: "Association of Novel Biomarkers of Cardiovascular Stress With Left Ventricular Hypertrophy and Dysfunction: Implications for Screening", JOURNAL OF THE AMERICAN HEART ASSOCIATION, vol. 2, no. 6, 7 November 2013 (2013-11-07), pages e000399 - e000399, XP055164537, DOI: 10.1161/JAHA.113.000399 *
XIAOYAN YIN: "Protein Biomarkers of New-Onset Cardiovascular Disease", ARTERIOSCLER THROMB VASC BIOL, 1 April 2014 (2014-04-01), pages 939 - 945, XP055164209, Retrieved from the Internet <URL:http://atvb.ahajournals.org/content/34/4/939.full.pdf> [retrieved on 20150122] *

Also Published As

Publication number Publication date
WO2015073709A2 (fr) 2015-05-21

Similar Documents

Publication Publication Date Title
WO2015073710A3 (fr) Détection du risque de maladie cardiovasculaire athéroscléreuse et du risque d&#39;infarctus du myocarde
IL253179A0 (en) Blood-based biomarkers for the diagnosis of coronary artery disease
WO2012054588A3 (fr) Dispositifs à conduits et procédés de détection et de traitement d&#39;analytes
HK1211475A1 (en) Combination therapy
GB2555628B (en) Main processor error detection using checker processors
EP3644220A4 (fr) Détection de signal d&#39;électrocardiogramme
EP3166482A4 (fr) Système et procédé pour distinguer un événement cardiaque du bruit dans un signal d&#39;électrocardiogramme (ecg)
EP3346913A4 (fr) Ensemble de cathéter comprenant des capacités de surveillance
WO2013030578A3 (fr) Procédé de détection de nucléosomes
EP3200697A4 (fr) Stéthoscope à infrasons pour la surveillance de processus physiologiques
SG11201501920PA (en) Diagnosis, prevention and treatment of diseases of the joint
IL247111A0 (en) Preventive or therapeutic agent for kidney disease
IL312551A (en) Grpr-antagonists for detection, diagnosis and treatment of grpr-positive cancer
DK3189653T3 (da) Kontaktcenter-anti-bedrageri-overvågnings-, -detektions- og -forebyggelsesløsning
HK1213789A1 (zh) 用於血脑屏障运输的多肽
WO2014197816A8 (fr) Nanocomplexes sensibles aux stimulus et leurs procédés d&#39;utilisation
FR3030284B1 (fr) Systeme d&#39;arrimage de securite, mousqueton utilisable pour un tel systeme et ensemble d&#39;arrimage comprenant un tel systeme
WO2015073709A3 (fr) Détection du risque de maladie cardiovasculaire athéroscléreuse et du risque d&#39;insuffisance cardiaque
PL3636774T3 (pl) Sposób wykrywania chorób wywołanych C. perfringens u zwierząt
JP2014054318A5 (fr)
HK1244881A1 (zh) 建立维多珠单坑给药方案以治疗患有易激惹肠病的患者的方法
EP3288452A4 (fr) Système et procédés non invasifs d&#39;utilisation d&#39;impédance pour la détection d&#39;un volume de liquide céphalo-rachidien
EP2741660A4 (fr) Dispositifs, systèmes et procédés de détection de coronaropathie
HUE042012T2 (hu) Nem-invazív eljárás születés elõtti magzati kromoszóma aneuploidia észlelésére anyai vérbõl
IT1402105B1 (it) Dispositivo indossabile per la diagnosi di patologie cardiache e/o per la rilevazione di variabili emodinamiche.

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14816478

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14816478

Country of ref document: EP

Kind code of ref document: A2